Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore

NPPA fixes retail prices for 41 drug combinations

The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis

NATCO Pharma updates on legal proceedings on Risdiplam launch in India

NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24

Merck reports 2024 sales at $64.2 billion

The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion